Physician profile
Khalid Hubeishy
NPI 1306930391
$222,167.75
in general payments reported to CMS, 2019-2025
23 companies · $61K in 2025
The $61K reported for 2025 was more than what 98% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,170 · 2020: $579 · 2021: $19K · 2022: $37K · 2023: $33K · 2024: $71K · 2025: $61K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $67K · Consulting Fee: $49K · Honoraria: $29K · Food and Beverage: $12K · Travel and Lodging: $7,222 · Education: $203.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $66,556.00 |
| Consulting Fee | $49,213.00 |
| Honoraria | $29,425.00 |
| Food and Beverage | $12,003.92 |
| Travel and Lodging | $7,221.99 |
| Education | $202.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $121,290.58 | 2019-2025 | Ingrezza |
| Axsome Therapeutics, INC. | $67,531.68 | 2023-2025 | Auvelity, Sunosi |
| Abbvie INC. | $24,512.00 | 2021-2025 | |
| Sunovion Pharmaceuticals INC. | $1,263.99 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,158.81 | 2019-2025 | Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,037.19 | 2020-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $834.94 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Otsuka America Pharmaceutical, INC. | $823.56 | 2019-2025 | Rexulti |
| Lundbeck LLC | $776.33 | 2019-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $654.85 | 2019-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Alkermes, INC. | $519.42 | 2021-2025 | Aristada, Lybalvi |
| Vanda Pharmaceuticals INC. | $440.05 | 2019-2025 | Fanapt, Hetlioz |
| Corium, LLC | $355.54 | 2022-2025 | Azstarys |
| Supernus Pharmaceuticals, INC. | $319.16 | 2022-2025 | Qelbree, Qelbree |
| Bausch Health US, LLC | $140.43 | 2019-2023 | Wellbutrin, Aplenzin |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $126.51 | 2019 | |
| Shire North American Group INC | $117.16 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $71.79 | 2024-2025 | Cobenfy |
| Idorsia Pharmaceuticals US INC | $68.03 | 2022-2024 | Quviviq |
| Almatica Pharma LLC | $62.81 | 2021-2023 | Loreev Xr |
| Noven Therapeutics, LLC | $29.07 | 2024 | Xelstrym |
| Merck Sharp & Dohme LLC | $18.30 | 2023 | Belsomra |
| Eisai INC. | $15.55 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Khalid Hubeishy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.